Crinone®

Learn more about

Brief Product Outline and Illustration

Questions about Crinone®?

Call our 24/7 toll-free support line at 1-800-387-8479 or submit your questions and comments using our online form.

Overview

Crinone® is a gel that is applied directly from a specially designed applicator into the vagina. The lining of the vagina is coated with the gel.

View instructions on how to administer Crinone®.

CRINONE® is a smooth white to off-white gel filled into vaginal applicators for single use.

Each applicator contains a slightly larger amount of gel than actually released, as the rest of the product tends to adhere to the inside of the applicator. It is therefore quite normal for a little gel to be left inside the applicator. Each applicator contains 1.45 g vaginal gel and is designed in such way that with each administration an exactly defined amount of gel (1.125 g) is delivered. Any content of gel remaining in the applicator after use must be discarded.

Crinone® is available at a strength of 90 mg/dose (8% gel) progesteroneprogesteronea hormone produced by the corpus luteum during the second half of a woman's menstrual cycle; it thickens the lining of the uterus to prepare it to accept implantation of a fertilized egg (note that mg stands for milligrams which is a unit measure).[1]

Crinone® is available in packages of 6 or 18 applicators. [1]

One application of Crinone® 8% (90 mg of progesteroneprogesteronea hormone produced by the corpus luteum during the second half of a woman's menstrual cycle; it thickens the lining of the uterus to prepare it to accept implantation of a fertilized egg) is used every day, starting the day of the embryoembryoa fertilized egg that has begun cell division transfer. In some cases, the dose can be increased to two applications of Crinone® 8% daily. If pregnancy occurs, treatment should be continued for up to 10 to 12 weeks. [1]

Crinone® is to be applied directly from the specially designed applicator into the vagina.

Crinone® (Progesterone gel) is used for luteal phase support in induced cycles such as In Vitro Fertilization (IVFin vitro fertilization (IVF)a procedure by which eggs produced by administering fertility drugs are retrieved from a woman's body and fertilized by sperm in a laboratory, and the resulting embryos are transferred by catheter to the uterus) cycles including oocyte donation recipients with or without functional ovaries.

Tell your doctor or pharmacist if:

  • you are allergic to any of the ingredients contained in CRINONE
  • you have abnormal vaginal bleeding
  • you have porphyria (congenital or acquired disorder of the biosynthesis of the red blood stain)
  • you have malignant disease of the breast or genital organs, or if such a disease is suspected
  • you have an acute blood clot including inflammation of superficial veins (thrombophlebitis), a vascular occlusion (thormboembolic disorder), or a cerebral apoplexy, or if you have had such disease before
  • you are pregnant with a non-viable fetus and/or if no heartbeat was detected (missed abortion)
  • you are using your own milk to feed a baby
  • you have liver disease, epilepsy, heart or kidney problems, or are using any other vaginal product

Crinone® should not be administered at the same time with other vaginal therapies. If other intravaginal therapy is to be used simultaneously, there should be at least a 6-hour period before or after Crinone® administration.

The following side effects have been reported with Crinone®: cramps, breast pain/pain in the soft tissue of chest/underarm, headache, pain, bloating, nausea, vaginal discharge, sleepiness, intermenstrual bleedingintermenstrual bleedingbleeding between periods, vaginal irritation and application-site reactions. [1]

There have been occasional reports of drowsiness associated with the use of Crinone®. Therefore, TAKE CARE if you intend to drive or operate machinery. If you experience these effects and they become troublesome, please consult your doctor. [1]

Crinone® gel should be stored at room temperature (15°C to 25°C) and not exposed to extreme heat or cold. As with all medications, the gel applicators should be kept in a safe place where children cannot reach them. Do not use Crinone® gel after the expiry date, which is printed on the label. [1]

  1. Crinone® Product Monograph. Date of Approval: July 04, 2023. EMD Serono, A Division of EMD Inc., Canada. Crinone is a registered trademark of Merck KGaA, Darmstadt, Germany or its affiliates.